Monoclonal gammopathies are found in patients with myeloma, lymphoid malignant disorders, and amyloidosis. They are also discovered in patients with other diseases, and even in healthy people over 70 years.' 2 In such cases monoclonal gammopathies are of undetermined significance, and therefore of little if any diagnostic value.
The aim of the present study was to evaluate the monoclonal gammopathies revealed in the course of investigation of patients with chest disease.
Methods
We reviewed the records of all patients referred to The miscellaneous disorders comprised systemic sclerosis with interstitial pulmonary disease; farmer's lung; two cases of pleural effusion associated with congestive heart failure (one of them with underlying Waldenstrom's disease); two cases of chronic obstructive pulmonary disease; eosinophilic pneumonia; and idiopathic pulmonary fibrosis with underlying Waldenstrom's disease.
The monoclonal gammopathy disappeared in five patients: in one with solitary plasmacytoma, after surgery; one with Hodgkin's disease and one with non-Hodgkin's lymphoma after complete remission under treatment; one with lung cancer who presented with infection while receiving chemotherapy; and one with pulmonary infection.
Discussion
Monoclonal gammopathy was a valuable guide to diagnosis in 17 of the 52 patients (33%). In 10 of them it was an indicator of myeloma or a lymphoproliferative disorder affecting the chest; in the remaining seven patients it was an indicator of such conditions affecting only extrathoracic sites, the chest disease having another origin. In the other seven cases the monoclonal gammopathy did not contribute to diagnosis, although a latent lymphoproliferative disease or "smouldering myeloma"4 cannot be excluded since more intensive investigation might have revealed a higher proportion of such conditions.
The heavy and light chain isotypes of the monoclonal components in this series were similar to those of a larger series from the same laboratory.3 In our study IgM gammopathies were always associated with lymphoproliferative disorders, and light chain gammopathies were in all cases associated with myeloma or lymphoproliferative disease.
Thoracic and pulmonary disease are only rarely initial features of plasma cell myeloma.' The chest radiographic appearance of a plasmacytoma is typically that of a homogeneous mass associated with an osteolytic rib lesion. This mass usually protrudes intrathoracically, and the association of such a radiological appearance with a monoclonal gammopathy is therefore highly suggestive of plasmacytoma of the rib. We have found electrophoretic and immunoelectrophoretic examination of the serum to be useful in the diagnosis of patients referred for investigation of chest disease. Where chest disease is accompanied by monoclonal gammopathy, plasma cell neoplasia or lymphoproliferative disease should be sought and chest disease caused by these disorders considered.
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